STOCK TITAN
  1. Home
  2. News
  3. NKTX

Nkarta to Participate at Upcoming Investor Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at this upcoming investor conference:

Cantor Virtual Global Healthcare Conference
Tuesday, September 28, 2021
4:00 p.m. ET - fireside chat presentation

A simultaneous webcast of the presentation will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately four weeks.

About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of cell therapy candidates generated by efficient manufacturing processes, which are engineered to enhance tumor targeting and improve persistence for sustained activity in the body. For more information, please visit the company’s website at www.nkartatx.com.

Nkarta Media/Investor Contact:
Greg Mann
Nkarta, Inc.
gmann@nkartatx.com

 


Stock NKTX logo
Nkarta, Inc.

NASDAQ:NKTX

NKTX Rankings

#3093 Ranked by Market Cap
#5374 Ranked by Stock Gains
N/A Ranked by Dividends

NKTX Latest News

Apr 3, 2024
Nkarta to Participate in Upcoming Investor Conferences
Mar 25, 2024
Nkarta Announces Pricing of $240 Million Underwritten Offering
Mar 21, 2024
Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
Feb 28, 2024
Nkarta to Participate in Upcoming Investor Conferences
Dec 9, 2023
Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition

NKTX Stock Data

450.99M
33.34M
5.16%
73.51%
6.89%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SOUTH SAN FRANCISCO

About NKTX

nkarta therapeutics seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies. nkarta was founded on the proprietary, robust and well characterized natural killer (nk) cell expansion technology pioneered by dario campana. the company is focused on leveraging the natural potent power of nk cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. nkarta is combining its nk expansion platform technology with proprietary cell engineering technologies to build differentiated autologous and allogeneic cell therapy candidates for the treatment of cancer. founded in 2015, the company’s investors include sr one, nea and novo ventures. for more information, please visit the company’s website at www.nkartatx.com.